Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins.

Authors

Joshua Loya
Charlie Zhang
Emily J Cox, Providence Sacred Heart Medical CenterFollow
Achal Singh Achrol, Department of Neurosurgery and Neurosciences, John Wayne Cancer Institute and Pacific Neuroscience Institute, Santa Monica, CA, USAFollow
Santosh Kesari, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.Follow

Document Type

Article

Publication Date

11-1-2019

Publication Title

CNS Oncol

Abstract

Management of high-grade gliomas remains a complex challenge. Standard of care consists of microsurgical resection, chemotherapy and radiation, but despite these aggressive multimodality therapies the overall prognosis remains poor. A major focus of ongoing translational research studies is to develop novel therapeutic strategies that can maximize tumor cell eradication while minimizing collateral side effects. Particularly, biological intratumoral therapies have been the focus of new translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two-part review will provide an overview of biological intratumoral therapies and summarize key advances and remaining challenges in intratumoral biological therapies for high-grade glioma. Part I focuses on discussion of the concepts of intratumoral delivery and immunotoxin therapies.

Clinical Institute

Cancer

Department

Oncology

Department

Neurosciences

Recommended Citation

Loya, Joshua; Zhang, Charlie; Cox, Emily J; Achrol, Achal Singh; and Kesari, Santosh, "Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins." (2019). Articles, Abstracts, and Reports. 2516.
https://digitalcommons.providence.org/publications/2516